神经科罕见病大盘点!

2020-05-29 MedSci MedSci原创

罕见病,又称“孤儿病”,是指发病率极低的疾病。根据WHO的定义,罕见病是患病人数占总人口0.65‰~1‰的一类疾病的统称,其中80%以上属于遗传性疾

罕见病,又称“孤儿病”,是指发病率极低的疾病。根据WHO的定义,罕见病是患病人数占总人口0.65‰~1‰的一类疾病的统称,其中80%以上属于遗传性疾病,且90%的罕见病是严重性疾病。目前,全球已知的罕见病有近7000种,约占人类疾病总数的10%。由于临床上较少遇见此类疾病,且大多数的疾病累及多个器官和系统,而临床医生对于疾病本身及其可能带来的全身多器官的累及缺乏全面系统的了解,患者的就医、诊断和治疗常常面临极大的困难。在此对目前神经科的罕见病进行盘点,以期为神经科临床医生初步介绍一下与神经系统相关的罕见病。 多巴反应性肌张力障碍(DRD) 又称Segawa病,该疾病由日本学者Segawa于1976年首次描述。该病的起病年龄平均为6岁,起病越早,症状越重。典型症状为:在6岁左右以一侧下肢马蹄内翻足起病。10岁左右时,一侧上肢出现姿势性震颤,在之后的10-15年,姿势性震颤扩展至所有肢体,伴随肌张力障碍性肌强直的加重。随着肌张力障碍的进展,运动迟缓见于所有的患者。其临床特点为症状的昼间波动性,以及小剂量多巴制剂持续有效是其显著的临床特征。用药后所有症状包括易疲劳、肌张力障碍、姿势异常、震颤

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2178515, encodeId=039621e8515f8, content=<a href='/topic/show?id=ccad8092032' target=_blank style='color:#2F92EE;'>#肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80920, encryptionId=ccad8092032, topicName=肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:48:07 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2178514, encodeId=eb8421e85143b, content=<a href='/topic/show?id=f094109483ff' target=_blank style='color:#2F92EE;'>#多巴反应性肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=109483, encryptionId=f094109483ff, topicName=多巴反应性肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:47:55 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=970803, encodeId=908f9e08034b, content=谢谢分享,收藏学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22d05511572, createdName=ms1000002047318983, createdTime=Fri Jun 04 09:58:56 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890311, encodeId=29bf89031176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2b5417310, createdName=ms7000001505175733, createdTime=Tue Oct 06 02:46:50 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881789, encodeId=cff6881e8911, content=非常有用,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=504b2388057, createdName=1232a1fem17(暂无昵称), createdTime=Tue Sep 01 14:59:25 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443682, encodeId=2037144368282, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467539, encodeId=ab14146e539d8, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600855, encodeId=262e600855eb, content=罕见病越来越受重视,🐴🐴🐝, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri May 29 23:45:58 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2024-01-01 ms5000001140735835 来自北京
  2. [GetPortalCommentsPageByObjectIdResponse(id=2178515, encodeId=039621e8515f8, content=<a href='/topic/show?id=ccad8092032' target=_blank style='color:#2F92EE;'>#肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80920, encryptionId=ccad8092032, topicName=肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:48:07 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2178514, encodeId=eb8421e85143b, content=<a href='/topic/show?id=f094109483ff' target=_blank style='color:#2F92EE;'>#多巴反应性肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=109483, encryptionId=f094109483ff, topicName=多巴反应性肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:47:55 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=970803, encodeId=908f9e08034b, content=谢谢分享,收藏学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22d05511572, createdName=ms1000002047318983, createdTime=Fri Jun 04 09:58:56 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890311, encodeId=29bf89031176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2b5417310, createdName=ms7000001505175733, createdTime=Tue Oct 06 02:46:50 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881789, encodeId=cff6881e8911, content=非常有用,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=504b2388057, createdName=1232a1fem17(暂无昵称), createdTime=Tue Sep 01 14:59:25 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443682, encodeId=2037144368282, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467539, encodeId=ab14146e539d8, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600855, encodeId=262e600855eb, content=罕见病越来越受重视,🐴🐴🐝, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri May 29 23:45:58 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2178515, encodeId=039621e8515f8, content=<a href='/topic/show?id=ccad8092032' target=_blank style='color:#2F92EE;'>#肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80920, encryptionId=ccad8092032, topicName=肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:48:07 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2178514, encodeId=eb8421e85143b, content=<a href='/topic/show?id=f094109483ff' target=_blank style='color:#2F92EE;'>#多巴反应性肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=109483, encryptionId=f094109483ff, topicName=多巴反应性肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:47:55 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=970803, encodeId=908f9e08034b, content=谢谢分享,收藏学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22d05511572, createdName=ms1000002047318983, createdTime=Fri Jun 04 09:58:56 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890311, encodeId=29bf89031176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2b5417310, createdName=ms7000001505175733, createdTime=Tue Oct 06 02:46:50 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881789, encodeId=cff6881e8911, content=非常有用,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=504b2388057, createdName=1232a1fem17(暂无昵称), createdTime=Tue Sep 01 14:59:25 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443682, encodeId=2037144368282, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467539, encodeId=ab14146e539d8, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600855, encodeId=262e600855eb, content=罕见病越来越受重视,🐴🐴🐝, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri May 29 23:45:58 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2021-06-04 ms1000002047318983

    谢谢分享,收藏学习。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2178515, encodeId=039621e8515f8, content=<a href='/topic/show?id=ccad8092032' target=_blank style='color:#2F92EE;'>#肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80920, encryptionId=ccad8092032, topicName=肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:48:07 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2178514, encodeId=eb8421e85143b, content=<a href='/topic/show?id=f094109483ff' target=_blank style='color:#2F92EE;'>#多巴反应性肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=109483, encryptionId=f094109483ff, topicName=多巴反应性肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:47:55 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=970803, encodeId=908f9e08034b, content=谢谢分享,收藏学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22d05511572, createdName=ms1000002047318983, createdTime=Fri Jun 04 09:58:56 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890311, encodeId=29bf89031176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2b5417310, createdName=ms7000001505175733, createdTime=Tue Oct 06 02:46:50 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881789, encodeId=cff6881e8911, content=非常有用,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=504b2388057, createdName=1232a1fem17(暂无昵称), createdTime=Tue Sep 01 14:59:25 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443682, encodeId=2037144368282, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467539, encodeId=ab14146e539d8, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600855, encodeId=262e600855eb, content=罕见病越来越受重视,🐴🐴🐝, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri May 29 23:45:58 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-10-06 ms7000001505175733

    值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2178515, encodeId=039621e8515f8, content=<a href='/topic/show?id=ccad8092032' target=_blank style='color:#2F92EE;'>#肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80920, encryptionId=ccad8092032, topicName=肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:48:07 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2178514, encodeId=eb8421e85143b, content=<a href='/topic/show?id=f094109483ff' target=_blank style='color:#2F92EE;'>#多巴反应性肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=109483, encryptionId=f094109483ff, topicName=多巴反应性肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:47:55 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=970803, encodeId=908f9e08034b, content=谢谢分享,收藏学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22d05511572, createdName=ms1000002047318983, createdTime=Fri Jun 04 09:58:56 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890311, encodeId=29bf89031176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2b5417310, createdName=ms7000001505175733, createdTime=Tue Oct 06 02:46:50 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881789, encodeId=cff6881e8911, content=非常有用,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=504b2388057, createdName=1232a1fem17(暂无昵称), createdTime=Tue Sep 01 14:59:25 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443682, encodeId=2037144368282, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467539, encodeId=ab14146e539d8, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600855, encodeId=262e600855eb, content=罕见病越来越受重视,🐴🐴🐝, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri May 29 23:45:58 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-09-01 1232a1fem17(暂无昵称)

    非常有用,感谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2178515, encodeId=039621e8515f8, content=<a href='/topic/show?id=ccad8092032' target=_blank style='color:#2F92EE;'>#肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80920, encryptionId=ccad8092032, topicName=肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:48:07 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2178514, encodeId=eb8421e85143b, content=<a href='/topic/show?id=f094109483ff' target=_blank style='color:#2F92EE;'>#多巴反应性肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=109483, encryptionId=f094109483ff, topicName=多巴反应性肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:47:55 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=970803, encodeId=908f9e08034b, content=谢谢分享,收藏学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22d05511572, createdName=ms1000002047318983, createdTime=Fri Jun 04 09:58:56 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890311, encodeId=29bf89031176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2b5417310, createdName=ms7000001505175733, createdTime=Tue Oct 06 02:46:50 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881789, encodeId=cff6881e8911, content=非常有用,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=504b2388057, createdName=1232a1fem17(暂无昵称), createdTime=Tue Sep 01 14:59:25 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443682, encodeId=2037144368282, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467539, encodeId=ab14146e539d8, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600855, encodeId=262e600855eb, content=罕见病越来越受重视,🐴🐴🐝, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri May 29 23:45:58 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2178515, encodeId=039621e8515f8, content=<a href='/topic/show?id=ccad8092032' target=_blank style='color:#2F92EE;'>#肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80920, encryptionId=ccad8092032, topicName=肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:48:07 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2178514, encodeId=eb8421e85143b, content=<a href='/topic/show?id=f094109483ff' target=_blank style='color:#2F92EE;'>#多巴反应性肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=109483, encryptionId=f094109483ff, topicName=多巴反应性肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:47:55 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=970803, encodeId=908f9e08034b, content=谢谢分享,收藏学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22d05511572, createdName=ms1000002047318983, createdTime=Fri Jun 04 09:58:56 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890311, encodeId=29bf89031176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2b5417310, createdName=ms7000001505175733, createdTime=Tue Oct 06 02:46:50 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881789, encodeId=cff6881e8911, content=非常有用,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=504b2388057, createdName=1232a1fem17(暂无昵称), createdTime=Tue Sep 01 14:59:25 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443682, encodeId=2037144368282, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467539, encodeId=ab14146e539d8, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600855, encodeId=262e600855eb, content=罕见病越来越受重视,🐴🐴🐝, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri May 29 23:45:58 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-05-31 syscxl
  8. [GetPortalCommentsPageByObjectIdResponse(id=2178515, encodeId=039621e8515f8, content=<a href='/topic/show?id=ccad8092032' target=_blank style='color:#2F92EE;'>#肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80920, encryptionId=ccad8092032, topicName=肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:48:07 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2178514, encodeId=eb8421e85143b, content=<a href='/topic/show?id=f094109483ff' target=_blank style='color:#2F92EE;'>#多巴反应性肌张力障碍#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=109483, encryptionId=f094109483ff, topicName=多巴反应性肌张力障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32c66456930, createdName=ms5000001140735835, createdTime=Mon Jan 01 02:47:55 CST 2024, time=2024-01-01, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=970803, encodeId=908f9e08034b, content=谢谢分享,收藏学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22d05511572, createdName=ms1000002047318983, createdTime=Fri Jun 04 09:58:56 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890311, encodeId=29bf89031176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2b5417310, createdName=ms7000001505175733, createdTime=Tue Oct 06 02:46:50 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881789, encodeId=cff6881e8911, content=非常有用,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=504b2388057, createdName=1232a1fem17(暂无昵称), createdTime=Tue Sep 01 14:59:25 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443682, encodeId=2037144368282, content=<a href='/topic/show?id=5b78e4414c7' target=_blank style='color:#2F92EE;'>#神经科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74414, encryptionId=5b78e4414c7, topicName=神经科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a4e5108341, createdName=12498f1em09(暂无昵称), createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467539, encodeId=ab14146e539d8, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sun May 31 14:19:04 CST 2020, time=2020-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600855, encodeId=262e600855eb, content=罕见病越来越受重视,🐴🐴🐝, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Fri May 29 23:45:58 CST 2020, time=2020-05-29, status=1, ipAttribution=)]
    2020-05-29 lovetcm

    罕见病越来越受重视,🐴🐴🐝

    0

相关资讯

辉瑞罕见病创新药维达全在中国获批

全球首个转甲状腺素蛋白稳定剂口服制剂维达全于2月5日获得中国国家药品监督管理局批准

支付方该如何看待真实世界证据用于罕见病?

药品研发、申请、审评、获批、上市后监管、报销,构成一个连续统一体。药品的最终消费者,是患者;患者使用药品,离不开支付方(payer),当罕见病、支付方、真实世界证据(real world evidence, RWE)这几个热点聚焦在一起时,孤儿药研发中,有什么成功的RWE用例?面临什么样的机遇和困难,不妨看看对欧、美国家支付方的调研结果。

诺华肿瘤两大事业部负责人确定

12月5日,诺华肿瘤(中国)总经理吉必成向员工宣布,任命现业务优化部负责人周游为诺华肿瘤(中国)罕见病事业部负责人,自2020年1月2日起生效;任命才华为诺华肿瘤(中国)血液事业部负责人,自2020年1月6日生效。

赛诺菲携3款罕见病新药亮相进博会: 为法布雷病、血友病及黏多糖贮积症患者带来新希望

2019年11月6日 ,全世界已知的罕见病约有7000种,但其中只有约6%的疾病有药可治。“去世前,希望能够用上一次药”是很多罕见病患者短暂生命中的唯一期盼。作为罕见病治疗领域的先行者和领导者,赛诺菲在第二届中国国际进口博览会上带来了三款罕见病领域的创新药物,以期助力中国法布雷病、B型血友病及黏多糖贮积症Ⅰ型患者直面健康挑战,绽放生命的希望。先行探索,积极推动罕见病药物可及性罕见病,又称孤儿病,是

Abeona Therapeutics的ABO-102基因疗法治疗罕见病,获得欧洲药品管理局的PRIME指定

Abeona Therapeutics宣布,欧洲药物管理局(EMA)已授予其ABO-102药物的PRIME称号,ABO-102是以腺相关病毒9(AAV9)为载体的基因疗法,开发用于治疗A型Sanfilippo综合症(MPS IIIA),这是一种罕见的溶酶体贮积病。

NEJM:JAK抑制剂ruxolitinib治疗遗传性USP18缺乏症

泛素特异性肽酶18(USP18)缺乏是一种严重的Ⅰ型干扰素病。USP18通过阻断Janus相关激酶1(JAK1)访问I型干扰素受体来下调I型干扰素信号传导。USP18的缺失会导致干扰素介导的炎症,这在围产期是致命的。我们报道了一例患儿,该患儿患有脑积水、坏死蜂窝织炎、全身炎症和呼吸衰竭的新生儿。外显子组测序鉴定出USP18上一个重要剪接位点的纯合子突变。编码蛋白有表达,但无负调控能力。用ruxol